Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 23,797-23,808 of 23,847
Other study type icon
CompletedNCT00376987

Zinc Supplements in Lowering Cadmium Levels in Smokers

This summary needs review. Please check the official study record and contact the research team for details.

In Winston-Salem
AddictionOtherFrom 21 Years to 120 Years
Countries
United States
Sponsor
Wake Forest University Health Sciences
Condition
Addiction
Drug study icon
TerminatedNCT00329108

Ziprasidone And Olanzapine's Outcomes In Mania

This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

Multiple locations, including Aachen
BipolarityDrugA study involving a medication or substance.From 18 Years to 65 Years
Countries
Germany, Greece, Italy, ...
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Bipolarity
Drug study icon
TerminatedNCT00248261

Ziprasidone and Sertraline in PTSD

This summary needs review. Please check the official study record and contact the research team for details.

In Hamburg
PTSDDrugOver 18 Years
Countries
Germany
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Condition
PTSD
Drug study icon
TerminatedNCT00374543

Ziprasidone for Generalized Anxiety in people with Bipolarity

This study exists to understand whether a therapy or guided support program is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to a therapy or guided support program in practice and what may need to be adjusted.

In Boston
Bipolarity, AnxietyDrugFrom 18 Years to 75 Years
Countries
United States
Sponsor
Massachusetts General Hospital
Condition
Bipolarity, Anxiety
Drug study icon
CompletedNCT01172652

Ziprasidone in Bipolarity With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)

This study exists to compare options and see whether a therapy or guided support program offers something meaningfully different. Researchers are trying to understand whether a therapy or guided support program can improve sleep, daily rhythms, and longer-term stability.

Multiple locations, including Palo Alto
Bipolarity, AnxietyDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
VA Palo Alto Health Care System
Condition
Bipolarity, Anxiety
Drug study icon
CompletedNCT01006551

Ziprasidone in Early Onset Schizophrenia Spectrum Disorders

This study exists to see whether a medication treatment is workable and worth testing more broadly. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

Multiple locations, including Medford
SchizophreniaDrugFrom 6 Years to 19 Years
Countries
United States
Sponsor
University of North Carolina, Chapel Hill
Condition
Schizophrenia
Drug study icon
CompletedNCT00622739

Ziprasidone in Pediatric Bipolarity

This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can give earlier or clearer feedback during care.

In Dallas
BipolarityDrugFrom 10 Years to 17 Years
Countries
United States
Sponsor
Baylor College of Medicine
Condition
Bipolarity
Drug study icon
CompletedNCT00635700

Ziprasidone in the Psychosis Prodrome

This study exists to explore whether this type of care could improve care and understanding. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

Multiple locations, including La Jolla
SchizophreniaDrugFrom 16 Years to 40 Years
Countries
United States, Canada
Sponsor
Yale University
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.